Matthew Shun-Shin Profile
Matthew Shun-Shin

@mshunshin

Followers
917
Following
450
Media
32
Statuses
660

Clinical Senior Lecturer and Consultant Cardiologist: AI, Echocardiography, valvular heart disease, improving device therapies for heart failure

London, England
Joined August 2011
Don't wanna be here? Send us removal request.
Explore trending content on Musk Viewer
@mshunshin
Matthew Shun-Shin
6 years
@ProfDFrancis Top tip for fellows: If you are unable to freely access a PDF of a study say, conducted using public money, written by freely by researchers, and peer-reviewed for free by others… Under no circumstance copy the Pubmed ID and then paste into sci-hub. tw to easily download
4
50
107
@mshunshin
Matthew Shun-Shin
6 years
All I want for Christmas is a.... #dontdisthehis @JACCJournals paper get it while it’s hot! His vs BiV in LBBB @DrAhranArnold @Dr_Keene
2
22
44
@mshunshin
Matthew Shun-Shin
5 months
ACC24 with two trials from Imperial TELE-ACS ( @rkhamis ), and ORBITA-COSMIC ( @rallamee - who is telling me to stop tweeting and get back to R).
@ACCinTouch
American College of Cardiology
5 months
🚨 #ACC24 Breaking News 🚨 The ACC.24 Late-Breaking Clinical Trials are out! Some of the trials being presented are: ◼️ RELIEVE-HF ◼️ EMPACT-MI ◼️ AEGIS-II ◼️ VICTORION-INITIATE ◼️ Step-HFpEF Dm ◼️ TELE-ACS Learn more & see the full list of trials:
4
71
207
3
5
36
@mshunshin
Matthew Shun-Shin
7 years
Thu 2nd Nov 2017. How to; tips and tricks; and, most excitingly - His Pacing for Heart Failure #UKHisPacing #dontdisthehis
Tweet media one
2
11
18
@mshunshin
Matthew Shun-Shin
7 years
. @RichardLehman1 's latest reviews features our SAMSON trial - n-of-1 trial for statin side effects.
Tweet media one
0
4
15
@mshunshin
Matthew Shun-Shin
8 months
It’s out.
@NEJM
NEJM
8 months
Presented at #AHA23 : ORBITA-2 trial: In patients with stable angina who were receiving little or no antianginal medication and had documented ischemia, PCI resulted in a better health status with respect to angina than placebo at 12 weeks. Full results:
13
148
410
1
0
15
@mshunshin
Matthew Shun-Shin
6 years
@ProfDFrancis @drjohnm I can trump your video - with this video from when the UK rolled out thrombolysis for acute stroke. (Watch with sound). I used it in a presentation in 2006. Anyway - the data for thrombectomy looks good - I think the UK is working out how/who to provide the service @LCC_DrMalik
1
5
14
@mshunshin
Matthew Shun-Shin
6 years
@venkmurthy @f2harrell @NEJM 1) Here is an R-notebook with the data and the “rms” style 7-level ordinal analysis. Hope I got it right! 2) You can customise the analysis to fit your personal ordering of the mRS (i.e. you may consider some states worse than death).
3
2
12
@mshunshin
Matthew Shun-Shin
7 years
Quick renal denervation meta-analysis. ABPM. Sham. From me in a BCN bar and @j_p_howard in LDN. @DrAfzalSohaib @escardio #ESCcongress
Tweet media one
2
10
11
@mshunshin
Matthew Shun-Shin
7 years
I often await Larry’s reviews almost as much as the trials. Some great comments and thoughts.
@cardiobrief
Larry Husten
7 years
Diving Deep Into The ORBITA Trial
Tweet media one
2
18
25
1
4
11
@mshunshin
Matthew Shun-Shin
7 years
Two failed LV lead attempts. #UKHisPacing - 15 minutes to pace His - narrowed QRS by 30ms. #dontdisthehis # @ImperialEP @DrAfzalSohaib
Tweet media one
Tweet media two
1
8
10
@mshunshin
Matthew Shun-Shin
7 years
It is well worth the 59.5Mb download.
@mshunshin
Matthew Shun-Shin
7 years
This - angio images of all 200 lesions available in appendix
0
1
1
0
3
9
@mshunshin
Matthew Shun-Shin
6 years
@drjohnm @skathire @PrashSanders @VinayPrasadMD @AndrewFoy82 @SVRaoMD @nmarrouche @Loftus In retrospect there was no point in changing the primary endpoint from mortality.
1
3
10
@mshunshin
Matthew Shun-Shin
6 years
Interesting editorial (and paper in circ). Top tip for fellows. Don’t google the first two references in it for the back story. It’s not at all interesting.
@CircAHA
Circulation
6 years
#Editorial : Undeniable evidence that the adult mammalian heart lacks an endogenous regenerative stem cell
1
31
41
2
2
8
@mshunshin
Matthew Shun-Shin
7 years
The late-breaking trial to watch is: ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease.
@crfheart
Cardiovascular Research Foundation
7 years
TCT NEWS! The Lineup Is In! View the Selected TCT 2017 Late-Breaking Clinical Trials & More
Tweet media one
0
3
3
1
4
9
@mshunshin
Matthew Shun-Shin
7 years
The first UK His Pacing Summit - Thu 2nd November 2017 @ RCP in London. #UKHisPacing #dontdisthehis
1
2
8
@mshunshin
Matthew Shun-Shin
6 years
Amazing - especially as @ImperialEP have probably done 1000 using the the research kit - phew.
@DrAfzalSohaib
Afzal Sohaib
6 years
Great to see Finapres based CRT optimization (TrueMax) on display at #EHRA2018 . Brainchild of @ProfDFrancis and @ZacharyWhinnett and now built into new Finapres models
Tweet media one
Tweet media two
0
4
3
0
0
8
@mshunshin
Matthew Shun-Shin
4 years
@ProfDFrancis 1.4 = exp((log(1.02)+log(1.91))/2)
1
0
8
@mshunshin
Matthew Shun-Shin
6 years
Though if Santa would like to bring us funding for an RCT as well that would be great... we have all been very good this year and almost finished recruitment for HOPE-HF #dontdisthehis
@mshunshin
Matthew Shun-Shin
6 years
All I want for Christmas is a.... #dontdisthehis @JACCJournals paper get it while it’s hot! His vs BiV in LBBB @DrAhranArnold @Dr_Keene
2
22
44
0
1
8
@mshunshin
Matthew Shun-Shin
4 years
@RicardoPetraco @MGtberg @rkhamis @rallamee @SukhNijjer @DrShaiSen @ghazala_yasin @MikhailGhada @DrIqbalMalikUK @drgrahamcole A patient coughing is an aerosol generating procedure. That is kind of how these respiratory diseases spread.
2
0
8
@mshunshin
Matthew Shun-Shin
7 years
The interventional trial of 2017 - ORBITA - the first placebo controlled trial of PCI in stable angina.
1
4
7
@mshunshin
Matthew Shun-Shin
6 years
Wow - as well as giving her views on PCI to the press, Rasha also found time to talk football to a major U.K. paper... #ORBITA @rallamee
Tweet media one
0
0
7
@mshunshin
Matthew Shun-Shin
4 years
@strain_rate @TorBiering @Matte_Cameli @lpbadano @denisamuraru @EchofirstB @ThorEdvardsen If you assume outcome is solely dependent on the AV plane motion - studies would still show that outcome were also associated with LV strain, LA Strain, and LA strain when LV strain were included in the model. Demonstration:
2
1
7
@mshunshin
Matthew Shun-Shin
6 years
Hey EPpeeps. Does anyone have the link to the real HRS abstract submission site? I can only find this one that changes $75 per abstract.
1
2
6
@mshunshin
Matthew Shun-Shin
7 years
Making slides for #UKHisPacing summit. @ImperialEP + @TheBHF ’s X-over RCT of DHBP for Heart Failure + long PR + narrow QRS #dontdisthehis
Tweet media one
0
4
7
@mshunshin
Matthew Shun-Shin
7 years
@f2harrell @NEJM Hypothetical numbers: No treatment - 50% have events; Rx A -10%, Rx B - 5%. A is tablet, needs monitoring; B is injection, painful. If C has event rate of 7.5% (or even 10%); but oral and no monitoring patient may prefer. The unknown anchoring rate of no treatment may be key.
1
1
6
@mshunshin
Matthew Shun-Shin
6 years
@venkmurthy @f2harrell @NEJM The raw data for the outcome would be a table of TrialID, the treatment arm, and the mRS at 30 days. This can be constructed from the figure and analysed. Click my notebook link -> took me 5 mins P.s Amazing Trial.
1
0
6
@mshunshin
Matthew Shun-Shin
7 years
@mirvatalasnag @jedicath No. Effective half life of Ticagrelor much shorter as reversible binding with P2Y reception. Stick with OD ASA and Clopi.
1
1
6
@mshunshin
Matthew Shun-Shin
7 years
@drjohnm @NEJM Based on this I think @TheLancet is the perfect journal for ORBITA.
Tweet media one
0
0
6
@mshunshin
Matthew Shun-Shin
4 years
@statsepi @ADAlthousePhD Nice line snuck in at the end - “In summary, authors should not attempt to get cute when performing survival analysis using composite endpoints. “
1
0
6
@mshunshin
Matthew Shun-Shin
4 years
Tune in today. 6pm U.K. time. With plenty of time for discussion!
@Collaboratory1
NIH Pragmatic Trials Collaboratory
4 years
📌 This Friday, Dec 18, Dr. @mshunshin of @ImperialNHLI will present findings from #SAMSONtrial , an n-of-1 trial to assess side effects of #statins compared with placebo and no treatment. Join us for our final Grand Rounds of the year! 🔗 #pctGR
Tweet media one
0
3
4
0
2
6
@mshunshin
Matthew Shun-Shin
6 years
@AdeMarvao @ProfDFrancis @drgrahamcole @DrJHoward Either way I am sticking to my Mediterranean diet of daily Pizza and Birra Moretti
0
0
6
@mshunshin
Matthew Shun-Shin
5 years
Yet, I'm sure I saw @ProfDFrancis eat a salad the other day...
@BostonChiefs
VA Joint Chiefs
5 years
...and this was our favorite statin study by far! #medtwitter #MedEd
Tweet media one
0
1
7
0
1
6
@mshunshin
Matthew Shun-Shin
6 years
@ProfDFrancis x = num min past 8 20 - x/12 = num mins to 12 on hour hand Then x = 20 - x/12 So x = 240 / 13 = 18 6 /13 mins.
0
0
5
@mshunshin
Matthew Shun-Shin
4 years
👍
@Medscape
Medscape
4 years
#SAMSONtrial will be this year’s #AHA20 virtual conference highlight, says @drjohnm .
0
4
14
0
0
5
@mshunshin
Matthew Shun-Shin
8 months
0
0
5
@mshunshin
Matthew Shun-Shin
7 years
CASTLE-AF. Looking forward to paper - why (in unblinded trial) curves similar until 36mo then sudden deterioration in control #ESCcongress
Tweet media one
2
4
5
@mshunshin
Matthew Shun-Shin
7 years
We are doing that in our SAMSON n-of-1 trial of statin side effects - - at Imperial College London 2/2
0
2
4
@mshunshin
Matthew Shun-Shin
6 years
@barttels2 @anupampom @f2harrell @venkmurthy @NEJM In this case I think it is for the intellectual exercise. More interesting to learn with actual data, and practice techniques + methods so that you can pre-specify them in your own work before you see the data. Message is 1) Amazing work by authors 2) Don’t have an OOH arrest.
1
0
4
@mshunshin
Matthew Shun-Shin
6 years
@drandrewsharp @DavidLBrownMD @venkmurthy @rallamee @dsutter111 @rwyeh @ProfDFrancis @SVRaoMD Well, ISIS-2 had good luck with sub-groups and birth star sign. @f2harrell - does Hmisc have a date to zodiac sign converter?
0
0
4
@mshunshin
Matthew Shun-Shin
7 years
@Hisdoc1 @D_Keene Thanks for the fantastic lectures and thoughts - and to another 24h of His pacing in Chicago.
0
2
4
@mshunshin
Matthew Shun-Shin
6 years
@venkmurthy @rwyeh @ProfDFrancis @VinayPrasadMD @johnwmcevoy @rallamee @f2harrell @DavidLBrownMD @ADAlthousePhD People may be very accurate when saying that something has not happened, but if it has happened, very bad at remembering how many times / often (so is effectively a random number). Consequently, only useful information may be absence/presence.
1
0
4
@mshunshin
Matthew Shun-Shin
6 years
@rwyeh @skathire @rallamee @ProfDFrancis I’m sitting next to @rallamee - she is signing up with new nom de plume as we speak :-)
1
0
4
@mshunshin
Matthew Shun-Shin
3 years
Errrr if 100% were abnormal it would also be unnecessary. If ~50% are abnormal then the referrals are mathematically perfect.
@bncs_imaging
BNCS_imaging
3 years
Moreover as 40% of cardiac CTs are normal, going forward we better pretest prediction to reduce unecessary testing
1
0
2
1
1
4
@mshunshin
Matthew Shun-Shin
6 years
@AdeMarvao @rafavidalperez @DrAfzalSohaib @rladeiraslopes Probably a few factors. 1)statistical 2) difficultly classifiying cause - can die of pump failure and then go into VT/VF 3) bulky vest reminds them to take 2ndry prevent Rx
1
1
4
@mshunshin
Matthew Shun-Shin
6 years
@DavidLBrownMD @rwyeh @venkmurthy @EpiEllie @boback @ethanjweiss @ajaykirtane @anish_koka @rallamee @mmamas1973 @fischman_david @DocSavageTJU @metrics52 Censor the patients when you lose to follow-up rather than exclude all those site’s data. You still want their early data in your analysis.
3
0
4
@mshunshin
Matthew Shun-Shin
6 years
@omaclaren @stephensenn If you want to have a neurosurgery hobby, start with this paper - Emergency burr holes “how to do it”. It features the invaluable advice "It may be useful to nominate a person to read out the components of this guide as the procedure is being performed”
0
1
4
@mshunshin
Matthew Shun-Shin
6 years
Great first post. Check out - a new project from @f2harrell for longer, more detailed discussions about #MedStats + Trials + more.
@f2harrell
Frank Harrell
6 years
Provocative interpretation of PARAMEDIC2 trial - inviting your participation in the discussion @
Tweet media one
1
6
15
0
0
4
@mshunshin
Matthew Shun-Shin
6 years
@AdeMarvao @drgrahamcole @ProfDFrancis @DrJHoward Well, it should be in the guideline, but as something you shouldn’t do.
1
0
4
@mshunshin
Matthew Shun-Shin
6 years
@rwyeh @skathire @rallamee @ProfDFrancis @rallamee will be presenting ANCOVA results at EuroPCR, with a little help from @f2harrell along the way.
1
0
4
@mshunshin
Matthew Shun-Shin
6 years
ORBITA-HQ Research meeting. Smiling faces after an evening of food, drink, and arguing about physiology, trials, and statistics. @rallamee @jerd10 @Yousifa19343425 @DrShaiSen @henselig @CCook_MD
Tweet media one
1
2
4
@mshunshin
Matthew Shun-Shin
4 years
@DrAfzalSohaib @RicardoPetraco @MGtberg @rkhamis @rallamee @SukhNijjer @DrShaiSen @ghazala_yasin @MikhailGhada @DrIqbalMalikUK @drgrahamcole Anyway, you should be able to get a PLAX and a few apical views in the length of time you can hold your breath. So nothing really to worry about.
0
0
4
@mshunshin
Matthew Shun-Shin
6 years
@drjasondungu
Dr Jason Dungu PhD FRCP FESC
6 years
Under appreciated phenomenon #pacing #heartfailure
2
7
12
0
2
4
@mshunshin
Matthew Shun-Shin
7 years
@AdeMarvao @DrAfzalSohaib Mechanism, haemodynamics, and physiology make sense - but need RCT. Our HOPE-HF trial for HF with long PR - but need more RCT for other Dz
1
0
3
@mshunshin
Matthew Shun-Shin
6 years
@EJSMD @SchakrabartiEP @SergioPinski @MDT_Cardiac To be fair to the trialists and @MDT_Cardiac it was a fantastic idea for a trial, but they estimated they would need to randomise 2300 subjects and only got 44 patients in 13 months. It showed willingness to fund and try - but sometimes you have to stop and re-consider.
1
1
3
@mshunshin
Matthew Shun-Shin
6 years
@BSHeartFailure Here is a clickable link - open access as well - so no need to sign in. Uses non-invasive, beat-by-beat finger BP to optimise CRT. Now built into the @finapres machine - so easy-peasy. Using this technique in the HOPE-HF trial #dontdisthehis
0
4
3
@mshunshin
Matthew Shun-Shin
7 years
Watching NN learn to segment LV. Power of open code+data @tensorflow library, @sunnybrook CMR, SegNet @alexgendall
Tweet media one
Tweet media two
Tweet media three
1
4
3
@mshunshin
Matthew Shun-Shin
4 years
@ncurzen If you have lot (9 segments!) of ischaemia and you don’t get sent for revasc it likely means there is something else very wrong with you - hence higher mortality. If you force the lines to be linear - then they will cross.
0
0
3
@mshunshin
Matthew Shun-Shin
6 years
@angioplastyorg @DavidLBrownMD @willsuh76 @SVRaoMD @GreggWStone @CardiacConsult @philgenereux @MartyMleon @mirvatalasnag @chadialraies @DrSheilaSahni @drdevireddy @ekgpdx @ProfDFrancis @rallamee Methods paper is available here (open access): Whilst it reports the use of headphones (+eye mask or GA) for blinding - dissapointingly no details on the music played. @rallamee
1
0
3
@mshunshin
Matthew Shun-Shin
6 years
If your blood pressure has recovered from the England penalties, it’s time for another #ORBITA article - Author replies to @TheLancet letters.
@lowninstitute
Lown Institute
6 years
"Applying a positive spin could have smoothed the reception of the trial, but as authors we have a duty to preserve scientific integrity." #ORBITA authors respond to critical letters in @TheLancet @ProfDFrancis @DrVikasSaini
Tweet media one
3
1
10
1
1
3
@mshunshin
Matthew Shun-Shin
7 years
@DrJHoward @ProfDFrancis They should probably send a few more.
1
0
3
@mshunshin
Matthew Shun-Shin
7 years
@DanMarkMD @ajaykirtane Change seen in the placebo group is not the placebo effect, just as the change seen in the intervention group is not the intervention effect
1
2
3
@mshunshin
Matthew Shun-Shin
7 years
@f2harrell @ProfDFrancis We have three blocks (each x4) - (1) Taking nothing (2) Placebo (3) Active Statin. Daily symptoms via smartphone.
1
2
3
@mshunshin
Matthew Shun-Shin
6 years
2
0
3
@mshunshin
Matthew Shun-Shin
6 years
10 minutes into his new job as health secretary, Matt Hancock starts to get to know the doctors...
Tweet media one
0
1
3
@mshunshin
Matthew Shun-Shin
6 years
@ADAlthousePhD @boback @JeremySussman STS and similar typically will be calculated away from the patient - e.g. the fellow prepping the MDT form in the evening for the following day. CHADS2-VASc calculated in head whilst taking history in clinic with patient with new AF. Hence the difference in complexity.
2
0
3
@mshunshin
Matthew Shun-Shin
6 years
Tweet media one
1
0
3
@mshunshin
Matthew Shun-Shin
7 years
Wonderful Monday journal roundup as ever from @RichardLehman1 and great to see another viewpoint on #ORBITA @rallamee
@bmj_latest
The BMJ
7 years
Astronaut brain, and the "hidden iceberg" of Type 2 diabetes in the US: It's @RichardLehman1 's journal reviews
Tweet media one
3
20
33
0
3
3
@mshunshin
Matthew Shun-Shin
1 year
@statsepi the give away is that they talk about selecting the right patient for the procedure rather than the right procedure for the patient after a non-positive RCT.
0
0
3
@mshunshin
Matthew Shun-Shin
6 years
The SDD (how much it may vary from one reading to another) for SBP on a 24h holter is around 11mmhg (e.g. from placebo arm of spyral off-med). Titrating to a 10 mmHg range will lead to chasing your tail. #ESH
@drandrewsharp
Andrew SP Sharp
6 years
#ESH New European HT guidelines: Narrow window to aim for in Coronary patients of 120-130/70-80. Harm outside of that window on both sides
Tweet media one
1
0
1
1
2
3
@mshunshin
Matthew Shun-Shin
6 years
@VinayPrasadMD @venkmurthy @orbita @rallamee @ProfDFrancis @drjohnm @adamcifu ORBITA-HQ has. Though mainly over a few pints and tears (interventional fellows) and laughs (imaging fellows) at a pub in West London rather than on twitter.
1
0
3
@mshunshin
Matthew Shun-Shin
7 years
@f2harrell Ha! Another lie learnt at medical school. As posting I had a feeling it was going to be one of those.
1
0
3
@mshunshin
Matthew Shun-Shin
4 years
@dr_benoy_n_shah @venkmurthy @vass_vassiliou @MarcDweck Re: RCTs - to really show that the marker should guide therapy you want to recruit all-comers (those with high and low marker values), randomise them to the therapy, then at analysis show there is an interaction between the biomarker at baseline and treatment effect. 1/n
1
1
3
@mshunshin
Matthew Shun-Shin
6 years
@SukhNijjer @RicardoPetraco @rallamee @DrShaiSen @ProfDFrancis Wait, did you go for a 3D cubic spline without inviting me and @DrJHoward ?
0
0
3
@mshunshin
Matthew Shun-Shin
7 years
@EricTopol @MedtechReed @matthewherper @TheLancet @nytimeshealth @ginakolata Exercise time has been positive in multiple placebo controlled trials of anti-angina agents - and their primary endpoint.
1
0
2
@mshunshin
Matthew Shun-Shin
4 years
@ProfDFrancis did you take a look at Table 2 before you put in your bulk order of IPE? #EVAPORATE
Tweet media one
1
0
2
@mshunshin
Matthew Shun-Shin
6 years
@scleroplex @ProfDFrancis Exactly, when people e-mail me for a paper, because I 100% have them nicely organised on my computer, I can send it to them immediately. I don’t, for example, have to then find my own paper in Pubmed, copy it into sci-hub, and then send it to the requester.
1
0
2
@mshunshin
Matthew Shun-Shin
6 years
@ProfDFrancis @drjohnm The irony is that it was posted on May 16, the same day the positive results of the WAKE-UP trial were presented at #ESOC2018 and published in NEJM #shouldhavegonetoesoc2018 #EUvsUS
0
0
3
@mshunshin
Matthew Shun-Shin
4 years
@GwilliamsPh @PH_Evidence We are looking forward to submitting a full paper soon - with a lot of more analysis of the individual patient results. We have some great graphs and visualisations ready!
2
1
3
@mshunshin
Matthew Shun-Shin
7 years
A phenomenal undertaking led by @rallamee . Everyone said it was impossible. #ORBITAtrial
0
1
3
@mshunshin
Matthew Shun-Shin
6 years
@ProfDFrancis @rwyeh @skathire @rallamee @f2harrell @SmithBIDMC @Changyushen312 Me and @DrJHoward have submitted a request to add this to everyones file; or perhaps @f2harrell could add to Hmisc. t.test <- function(...){print("Banned, please use ANCOVA”)}
1
0
3
@mshunshin
Matthew Shun-Shin
6 years
For some variety put the higher blood pressures on the left hand side of the x-axis
@JACCJournals
JACC Journals
6 years
BP too high or too low at presentation of aortic dissection associated with higher mortality: . #JACC
Tweet media one
0
19
23
0
0
3
@mshunshin
Matthew Shun-Shin
6 years
@MedCrisis @EJSMD @willsuh76 @True_EP @raj_mehta @venkmurthy @f2harrell @narrowQRS @ProfDFrancis @syrton71 @dr_chirumamilla @OSUWexMed @drjohnm @DrQuinnCapers4 @fischman_david @DocSavageTJU @bcostelloMD @haiderwarraich @ADAlthousePhD @andreanatalemd @LuigiDiBiaseMD @Zo_EP2 Yes. Fundamentally, RCTs are an experiment. Whether you think / believe / are sure a procedure “works” or "doesn’t work” is orthogonal to why you conduct an experiment. We were sure PCI worked - but were curious by how much - and how it interacted with stenosis parameters.
1
0
3
@mshunshin
Matthew Shun-Shin
7 years
Free registration. Consultants, SpRs, Nurses, and Physiologists welcome. #UKHisPacing #dontdisthehis
@mshunshin
Matthew Shun-Shin
7 years
Thu 2nd Nov 2017. How to; tips and tricks; and, most excitingly - His Pacing for Heart Failure #UKHisPacing #dontdisthehis
Tweet media one
2
11
18
0
2
3
@mshunshin
Matthew Shun-Shin
4 years
@lpbadano @strain_rate @TorBiering @Matte_Cameli @denisamuraru @EchofirstB @ThorEdvardsen I think the message from the quick simulation should be that as we try at tease apart the mechanistic contribution of these imaging biomarkers we will need to take careful statistical advice.
1
0
3
@mshunshin
Matthew Shun-Shin
6 years
@DrFuSiongNg @DrAfzalSohaib Did patients at some centres really have to pay for assigned treatment? Primary source? If so that is all the more reason you cannot trust the ‘as treated’ analysis as the richer you are the better your outcomes are irrespective of treatment. #CABANA
2
0
2
@mshunshin
Matthew Shun-Shin
6 years
@ADAlthousePhD @DavidLBrownMD @rallamee @rwyeh @ProfDFrancis @RogueRad @venkmurthy @ajaykirtane Ah. ‘Negative’ is a description of the study data+criteria; not interpretation of data. We can separate. Better to call these trials as negative as greater harm in medical history has come from use of poorly tested therapies with weak data than having ‘negative’ outlook.
1
0
2
@mshunshin
Matthew Shun-Shin
6 years
@drjohnm @hswapnil Re: ICD with NICM. It is likely that ICDs now are just (or more so) efficacious at terminating spontaneous otherwise fatal tachyarrhythmias. The RR/HR/OR (forgive me @f2harrell ) for this specific death should be ~preserved. The baseline incidence will have decreased with time...
1
0
2
@mshunshin
Matthew Shun-Shin
6 years
We have some great #dontdisthehis science to submit. Just need the correct link for HRS abstracts. @HRSonline @drjohnm
@mshunshin
Matthew Shun-Shin
6 years
Hey EPpeeps. Does anyone have the link to the real HRS abstract submission site? I can only find this one that changes $75 per abstract.
1
2
6
0
1
2